EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA ...

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory ...

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis - Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted ...

The scientists supposedly all had access to sensitive government research, and the nature of their work has led to ...

As Health Secretary Robert F. Kennedy Jr. prepares to wean the country off mental health medications, U.S. Health Department ...

With cutting-edge sports medicine and sci-fi gadgetry, more and more athletes are figuring out how to extend their careers.

Before Lerone Martin joined Stanford in 2022 as director of the Martin Luther King Jr. Research and Education Institute, he ...

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of- ...

One day, I got a call from Peter Bahouth, a former Greenpeace honcho whom Ted Turner had swiped to run his grant-making ...

The Court examined whether criminal proceedings could be quashed despite serious allegations involving disrespect to a national icon. It held that genuine remorse and educational reform satisfied the ...

When scientist J. Craig Venter and his team announced in 2010 that they had created the first cell controlled by a fully synthetic genome, it marked a turning point in how scientists think about life.

Sunoco LP (NYSE: SUN) ("SUN" or the "Partnership") and SunocoCorp LLC (NYSE: SUNC) ("SUNC") today reported financial and operating results for the quarter ended March 31, 2026.